2014
DOI: 10.1007/978-1-4939-1598-9_1
|View full text |Cite
|
Sign up to set email alerts
|

Fundamentals of Amorphous Systems: Thermodynamic Aspects

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
13
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 13 publications
(13 citation statements)
references
References 18 publications
0
13
0
Order By: Relevance
“…8-10 PLGA-based MS systems have been successfully applied for controlled release in the knee joints while minimizing the systemic exposure. However, since molecules in the amorphous form are thermodynamically less stable than in the crystalline form, 16 it often causes chemical degradation in the matrix during storage or even after in vivo administration. 11 Currently, different preparation methods are used to fabricate micro-/nano-sized drug carriers, including emulsification and solvent evaporation and/or extraction, phase separation, and spray-drying.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…8-10 PLGA-based MS systems have been successfully applied for controlled release in the knee joints while minimizing the systemic exposure. However, since molecules in the amorphous form are thermodynamically less stable than in the crystalline form, 16 it often causes chemical degradation in the matrix during storage or even after in vivo administration. 11 Currently, different preparation methods are used to fabricate micro-/nano-sized drug carriers, including emulsification and solvent evaporation and/or extraction, phase separation, and spray-drying.…”
Section: Introductionmentioning
confidence: 99%
“…In these fabrication processes, in general, the active compounds are molecularly distributed in the polymeric matrix in the amorphous form. However, since molecules in the amorphous form are thermodynamically less stable than in the crystalline form, it often causes chemical degradation in the matrix during storage or even after in vivo administration. Moreover, uncontrolled recrystallization may occur during preparation and/or storage, changing the drug release pattern from the MS.…”
Section: Introductionmentioning
confidence: 99%
“…1). 56 Amorphous nanoparticles have liquid-like properties at the molecular level, but solid-like properties at the macroscopic level. Heat content or changes in molar volume (Y) with changes in temperature (X) are the important characteristics defining the behavior of amorphous drugs.…”
Section: Properties Of Amorphous Nanoparticlesmentioning
confidence: 99%
“…The ordered arrangement (crystals) is in the top portion and the disordered arrangement (amorphous) is in the bottom portion. Reproduced with permission from Bellantone 56.…”
mentioning
confidence: 99%
“…The definition of 'short-range' vs long-range' which divides amorphous from crystalline solids is subject to interpretation. Crystalline materials have, for example, been depicted as including order (symmetry operators) over at least 1000 individual molecules (Bellantone, 2014). If one considers an 'average' small drug molecule such as indomethacin (with a Mw of 357.…”
Section: Introductionmentioning
confidence: 99%